lufotrelvir
Sign in to saveAlso known as PF07304814, PF-07304814
Lufotrelvir (PF-07304814) is an antiviral drug developed by Pfizer which acts as a 3CL protease inhibitor. It is a prodrug with the phosphate group being cleaved in vivo to yield the active agent PF-00835231. Lufotrelvir is in human clinical trials for the treatment of COVID-19, and shows good activity against COVID-19 including several variant strains, but unlike the related drug nirmatrelvir it is not orally active and must be administered by intravenous infusion, and so has been the less favoured candidate for clinical development overall.
Wikidata facts
- Subclass of
- organophosphate
- Mass
- 552.198515266
Show 5 more facts
- isomeric SMILES
- CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)COP(=O)(O)O)NC(=O)C2=CC3=C(N2)C=CC=C3OC
- canonical SMILES
- CC(C)CC(C(=O)NC(CC1CCNC1=O)C(=O)COP(=O)(O)O)NC(=O)C2=CC3=C(N2)C=CC=C3OC
- chemical formula
- C₂₄H₃₃N₄O₉P
- subject has role
- prodrug
- Commons category
- Lufotrelvir
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Lufotrelvir (PF-07304814) is an antiviral drug developed by Pfizer which acts as a 3CL protease inhibitor. It is a prodrug with the phosphate group being cleaved in vivo to yield the active agent PF-00835231. Lufotrelvir is in human clinical trials for the treatment of COVID-19, and shows good activity against COVID-19 including several variant strains, but unlike the related drug nirmatrelvir it is not orally active and must be administered by intravenous infusion, and so has been the less favoured candidate for clinical development overall.
== See also == 3CLpro-1 Bemnifosbuvir Baloxavir marboxil Favipiravir GC376 GRL-0617 Molnupiravir Remdesivir Ribavirin Rupintrivir S-217622 Triazavirin
Excerpted from Wikipedia’s “lufotrelvir” article, available under the CC BY-SA 4.0 licence.